BioVentrix has completed patient enrolment in a pilot human clinical trial of its PliCath HF heart failure treatment system.

The PliCath HF system reduces ventricular volume, allowing the heart to pump properly and maintain perfusion to the body without excessive stress on the muscle of the heart wall.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

To date, 12 patients have showed an average indexed left ventricular end systolic volume reduction of 31%, with an improvement in ejection fraction.

BioVentrix medical advisor Andrew Wechsler said that the PliCath HF device enables significant left ventricular volume, resulting in the restoration of cardiac function without the risk of cutting into the heart or the need for cardiopulmonary bypass.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact